[Treatment of lower risk myelodysplastic syndromes].
Traitement des syndromes myélodysplasiques de bas risque.
ASE
ESA
Lenalidomide
Luspatercept
Lénalidomide
MDS
SMD
TPO agonists
agonistes TPO
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
11
01
2023
accepted:
15
02
2023
medline:
13
11
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
For low-risk myelodysplastic syndromes, the goal of treatment is to correct cytopenias or their consequences. Erythropoiesis-stimulating agents have an important role in the management of anemia. In this chapter, we will detail the response to ESAs, the factors predictive of response to ESAs. However, the search for new therapeutic options for low-risk, ESA-resistant MDS remains necessary as the incidence of AML transformation of the patients is higher. We can retain luspatercept for MDS with excess ring of sideroblasts, lenalidomide, and some molecules currently being tested such as imetelstat or roxedustat. However, the search for new therapeutic options for ESA-resistant low-risk MDS remains necessary. We can use androgenotherapy or TPO agonists in limited access for symptomatic thrombocytopenia.
Identifiants
pubmed: 37500385
pii: S0007-4551(23)00282-5
doi: 10.1016/j.bulcan.2023.02.027
pii:
doi:
Substances chimiques
Lenalidomide
F0P408N6V4
Hematinics
0
Types de publication
English Abstract
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
1156-1161Informations de copyright
Copyright © 2023. Published by Elsevier Masson SAS.